Primate-specific BTN3A2 protects against SARS-CoV-2 infection by interacting with and reducing ACE2Research in context

Summary: Background: Coronavirus disease 2019 (COVID-19) is an immune-related disorder caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The complete pathogenesis of the virus remains to be determined. Unraveling the molecular mechanisms governing SARS-CoV-2 interactions with...

Full description

Bibliographic Details
Published in:	EBioMedicine
Main Authors:	Ling Xu, Dandan Yu, Min Xu, Yamin Liu, Lu-Xiu Yang, Qing-Cui Zou, Xiao-Li Feng, Ming-Hua Li, Nengyin Sheng, Yong-Gang Yao
Format:	Article
Language:	English
Published:	Elsevier 2024-09-01
Subjects:	BTN3A2 SARS-CoV-2 Spike protein ACE2 COVID-19
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352396424003177

Similar Items

Specific T-Cell Immune Response to SARS-CoV-2 Spike Protein over Time in Naïve and SARS-CoV-2 Previously Infected Subjects Vaccinated with BTN162b2
by: Natali Vega-Magaña, et al.
Published: (2022-07-01)

Comprehensive Analysis of the Prognostic Value and Immune Infiltration of Butyrophilin Subfamily 2/3 (BTN2/3) Members in Pan-Glioma
by: Dong He, et al.
Published: (2022-08-01)

Glycyrrhizin Inhibits SARS-CoV-2 Entry into Cells by Targeting ACE2
by: Ming-Feng He, et al.
Published: (2022-10-01)

Research Progress on the Cardiac Injury from ACE2 Targeting in SARS-CoV-2 Infection
by: Hao Sun, et al.
Published: (2021-01-01)

Determinants of susceptibility to SARS-CoV-2 infection in murine ACE2
by: Takashi Kondo, et al.
Published: (2025-06-01)

The inactivation of the Niemann Pick C1 cholesterol transporter restricts SARS-CoV-2 entry into host cells by decreasing ACE2 abundance at the plasma membrane
by: Piergiorgio La Rosa, et al.
Published: (2024-12-01)

Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins
by: Sai Priya Anand, et al.
Published: (2020-09-01)

Interspecies transmission of SARS CoV-2 with special emphasis on viral mutations and ACE-2 receptor homology roles
by: Mervat E. Hamdy, et al.
Published: (2023-12-01)

Integrated microfluidics-based construction of anti-BTN2A2 gel droplet cell preparations for non-invasive tumor-infiltrating lymphocyte therapy
by: Yishen Tian, et al.
Published: (2025-04-01)

Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles
by: Canhao Wu, et al.
Published: (2022-03-01)

Possible Transmission Flow of SARS-CoV-2 Based on ACE2 Features
by: Sk. Sarif Hassan, et al.
Published: (2020-12-01)

A Suitable Membrane Distance Regulated by the RBD_ACE2 Interaction is Critical for SARS‐CoV‐2 Spike‐Mediated Viral Invasion
by: Mengdan Wu, et al.
Published: (2023-10-01)

ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives
by: Federica Saponaro, et al.
Published: (2020-09-01)

Evaluation of inflammatory biomarkers and their association with anti-SARS-CoV-2 antibody titers in healthcare workers vaccinated with BNT162B2
by: Ester Leno-Duran, et al.
Published: (2024-08-01)

In Vitro Inhibitory Effect of Nigella sativa L. Extracts on SARS-COV-2 Spike Protein-ACE2 Interaction
by: Najma Ali, et al.
Published: (2024-01-01)

BTN3A3 inhibits the proliferation, migration and invasion of ovarian cancer cells by regulating ERK1/2 phosphorylation
by: Sihan Chen, et al.
Published: (2022-08-01)

SARS-CoV-2 omicron spike simulations: broad antibody escape, weakened ACE2 binding, and modest furin cleavage
by: M. Zaki Jawaid, et al.
Published: (2023-10-01)

The ACE2 decoy receptor can overcome immune escape by rapid mutating SARS-CoV-2 variants and reduce cytokine induction and clot formation
by: Ming-Shiu Lin, et al.
Published: (2025-06-01)

Arthropod Ectoparasites Have Potential to Bind SARS-CoV-2 via ACE
by: Su Datt Lam, et al.
Published: (2021-04-01)

Changes within the P681 residue of spike dictate cell fusion and syncytia formation of Delta and Omicron variants of SARS-CoV-2 with no effects on neutralization or infectivity
by: Alona Kuzmina, et al.
Published: (2023-06-01)

Transcriptomics of mussel transmissible cancer MtrBTN2 suggests accumulation of multiple cancer traits and oncogenic pathways shared among bilaterians
by: E. A. V. Burioli, et al.
Published: (2023-10-01)

<i>In Silico</i>, <i>In Vitro</i> and <i>In Cellulo</i> Models for Monitoring SARS-CoV-2 Spike/Human ACE2 Complex, Viral Entry and Cell Fusion
by: Delphine Lapaillerie, et al.
Published: (2021-02-01)

An antibody targeting an immune checkpoint molecule BTN2A2 enhances anti-tumor immunity
by: Li Xiao, et al.
Published: (2025-07-01)

ACE2-Decorated Virus-Like Particles Effectively Block SARS-CoV-2 Infection
by: Bayraktar C, et al.
Published: (2024-07-01)

Transcriptional regulation of SARS-CoV-2 receptor ACE2 by SP1
by: Hui Han, et al.
Published: (2024-02-01)

Coronil effectively inhibits the interaction of clinically relevant Omicron mutants of SARS-CoV-2 spike proteins with human ACE2 receptor
by: Acharya Balkrishna, et al.
Published: (2025-02-01)

A Neutralization Assay Based on Pseudo-Typed Lentivirus with SARS CoV-2 Spike Protein in ACE2-Expressing CRFK Cells
by: Yalçın Pısıl, et al.
Published: (2021-02-01)

Potential inhibitors for blocking the interaction of the coronavirus SARS-CoV-2 spike protein and its host cell receptor ACE2
by: Changzhi Li, et al.
Published: (2022-07-01)

Investigation of some plant stilbenoids and their fragments for the identification of inhibitors of SARS-CoV-2 viral spike/ACE2 protein binding
by: Cyril T. Namba-Nzanguim, et al.
Published: (2024-06-01)

Secondary Publication: SARS-CoV-2 and Immunological Response
by: Hidehito Kato, et al.
Published: (2021-06-01)

A Safe and Accessible Cell-Based Spike–ACE2 Binding Assay for Evaluating SARS-CoV-2 Neutralization Activity in Biological Samples Using Flow Cytometry
by: Martin A. Rossotti, et al.
Published: (2025-09-01)

Decoy peptides effectively inhibit the binding of SARS-CoV-2 to ACE2 on oral epithelial cells
by: Lai-Keng Loi, et al.
Published: (2023-12-01)

Importance of ACE2 for SARS-CoV-2 Infection of Kidney Cells
by: Marie-Kristin Kroll, et al.
Published: (2023-03-01)

Phage Display-Derived Compounds Displace hACE2 from Its Complex with SARS-CoV-2 Spike Protein
by: Marc Sevenich, et al.
Published: (2022-02-01)

Inhibition of SARS-CoV-2 Spike Protein Pseudotyped Virus Infection Using ACE2-Tethered Micro/Nanoparticles
by: Soha Y. Alkhaldi, et al.
Published: (2023-05-01)

Relationship of ACE1 and ACE2 genetic polymorphisms on SARS-CoV-2 infection and severity of symptoms in different regions of Iraq
by: Bilal Ali Khashan, et al.
Published: (2024-02-01)

A Pathway Model to Understand the Evolution of Spike Protein Binding to ACE2 in SARS-CoV-2 Variants
by: Ludovico Pipitò, et al.
Published: (2022-10-01)

Role of tannic acid against SARS-cov-2 cell entry by targeting the interface region between S-protein-RBD and human ACE2
by: Xi Chen, et al.
Published: (2022-08-01)

A Multi-Targeting Approach to Fight SARS-CoV-2 Attachment
by: Luciano Pirone, et al.
Published: (2020-08-01)

ACE2 receptor polymorphism in humans and animals increases the risk of the emergence of SARS-CoV-2 variants during repeated intra- and inter-species host-switching of the virus
by: Christian A. Devaux, et al.
Published: (2023-07-01)